Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

12.87 -0.12 (-0.92%)
Delayed Quote Updated: 2:20 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 Next >
News headline image
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
From Contineum Therapeutics
Via Business Wire
News headline image
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at September Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
From Contineum Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.